|Bid||11.35 x 1000|
|Ask||11.80 x 800|
|Day's Range||11.40 - 11.96|
|52 Week Range||9.83 - 16.90|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
Ahmad said Prevail’s leading asset PR001 has a potentially large indication for treating Parkinson’s via disease-modifying therapy. PR001 could also potentially be the first therapy ever approved for treatment of neuronopathic Gaucher disease. In addition, Ahmad said PR006 for frontotemporal dementia and PR004 for synucleinopathies are also potential sources of long-term value creation for Prevail investors.
Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation. “We are pleased that the FDA has granted Fast Track Designation for PR001, which underscores the unmet need of patients with Parkinson’s disease with a GBA1 mutation, a chronic and progressive neurodegenerative disorder that comprises 7% to 10% of the total Parkinson’s disease population worldwide,” said CEO Asa Abeliovich.
Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company’s lead gene therapy program, PR001, for the treatment of Parkinson’s disease patients with a GBA1 mutation (PD-GBA). PR001 is a potentially disease-modifying, single-dose, AAV9-based gene therapy being developed for the treatment of PD-GBA and neuronopathic Gaucher disease.
New York-based Prevail Therapeutics (NASDAQ: PRVL ) opened for trade Thursday afternoon at $15.31 per share. The 7.353-million share IPO was priced at $17. Prevail is a gene therapy company founded in ...
Prevail Therapeutics Inc. , a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share.
Want to partake in the gene therapy revolution that is emerging as a new paradigm in drug development? New York-based Prevail Therapeutics is planning a 7.353-million share IPO, estimated to be priced between $16 and $18, according to the S-1/A filing from June 10. The company has applied for listing its shares on the Nasdaq under the ticker symbol PRVL.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...